Speaker illustration

Doctor Alexander Peikert

Medical University of Graz, Graz (Austria)

Member of:

European Society of Cardiology

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: State-of-the art treatment of HFmrEF and HFpEF in 2023

Thumbnail

Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 4

Thumbnail

Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 2

Thumbnail

Need of Treating Residual Inflammatory Activity in Coronary Heart Disease: the value of high sensitive CRP and LDL in a Real World Cohort.

Event: ESC Congress 2018

Topic: Inflammation and Immunity

Session: Inflammation and immunity in acute coronary syndromes

Thumbnail